Market Research Report
Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022
|Published by||MarketsandMarkets||Product code||556899|
|Published||Content info||155 Pages
Delivery time: 1-2 business days
|Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022|
|Published: September 14, 2017||Content info: 155 Pages||
The global PDX models market is estimated to grow at a CAGR of 16.7% from 2017 to 2022, to reach USD 167.6 million. The key factors driving the growth of the overall PDX models market include the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. However, the high cost of personalized PDX models and stringent guidelines regarding the ethical use of animals in cancer research are expected to restrain the growth of this market during the forecast period.
Based on tumor type, the PDX models market is segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck cancer, sarcoma, and melanoma. During the forecast period, the respiratory tumor models segment is expected to register the highest CAGR. Growth in this segment is mainly driven by the increasing focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in lung cancer treatment, as lung cancer is the leading cause of cancer-related deaths across the globe.
Asia Pacific is expected to grow at the highest CAGR in the global PDX models market during the forecast period of 2017-2022. Strong research expenditure and the well-structured CRO industry in China, growth in biomedical & medical research in Japan, rising pharmaceutical R&D expenditure in India, and rising translational and biomedical research in Singapore are expected to drive the market growth during the forecast period.
Break of primary participants was as mentioned below:
The various players in the PDX models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).
The report analyzes the PDX models market and aims at estimating the market size and the future growth potential of this market based on various segments such as type, tumor type, application, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies.
This report provides insights on the following pointers:
*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.